Cambridge, UK - PIR is delighted to announce that Dr Darrin Disley, parallel life science entrepreneur, angel investor and enterprise champion is to speak at the PiR CEO Breakfast Forum in Cambridge on Tuesday 17 January.

Disley has been involved in the start-up and growth of numerous business ventures, securing over $320 million in business financing from grant, angel, corporate, venture capital and public market sources as well as closing over $500 million of product, service, licensing and M&A deals.

As the CEO and President of Horizon Discovery Group plc, Disley led the company from a $275 thousand seed funding venture in 2008 to a $118 million IPO (2.8x oversubscribed) six years later. The funds raised by the IPO set a record for a life science company on the AIM market, with the company becoming the second largest research tools company on any market of the London Stock Exchange.

Horizon is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health. The company supplies over 23,000 products and related research services to over 1,600 unique research organisations engaged in the elucidation of the genetic basis of disease and the development of personalised medicine. In addition to this, the company’s own R&D pipeline is focused on developing novel molecular, cell and gene therapies capable of having significant impact on the treatment of common and rare diseases.

In his address at the PiR CEO Breakfast Forum, Disley will provide his vision of the future healthcare paradigm as the population ages and will bring out the need to address this with multidisciplinary science and academic-industry partnership, working with open innovation models within an entrepreneurial ecosystem that are capable of exploiting the current favourable R&D, tax, regulatory and investment framework.

“We are delighted that Darrin Disley has been able to join our event to give us all better insight into the extraordinary developments taking place at Horizon and beyond. I am sure that delegates will find his insights into a multidisciplinary approach to targeted cancer therapies inspiring and informative,” comments Sally Hope, CEO of PiR.

About PiR PiR is a specialist recruitment company focused exclusively on delivering the best talent to the international life science sector through executive search, interim management, talent management/mapping and innovative recruitment services. With a team that is functionally aligned, combined with life science recruitment experience of over 40 years, PiR provides a depth of expertise across key business functions at leadership and expert level. Our expertise is particularly evident across functions in high demand. These include Advanced Therapies, Medical, Regulatory, Programme Management, Market Access, Health Economics and Outcomes Research (HEOR), Pricing and Reimbursement as well as Translational Medicine. For further information, please visit www.pir-resourcing.com.

About Darrin M Disley, PhD Darrin is a parallel entrepreneur, angel investor and enterprise champion. He has been involved in the start-up and growth of numerous business ventures, securing over $320 million business financing from grant, angel, corporate, venture capital and public market sources as well as closing over $500 million of product, service, licensing and M&A deals. He is currently the CEO and President of Horizon Discovery Group plc, a company he led from a $275 thousand seed funding in March 2008 to a $113 million fund-raise at IPO (2.8x oversubscribed) exactly six years later. The funds raised by the IPO set a record for a life science company on the AIM market and were the second largest by any research tools company in a London listing. In 2012, he was named Business Leader of the Year at the European Life Science Awards, in 2014 was named Biotech and Pharma Executive of the Year by Scrip and in 2015 was named UK Quoted Company Entrepreneur of the Year, Cambridge Business Person of the Year and one of the 175 Faces of Chemistry by the Royal Society of Chemistry. Darrin supports education, entrepreneurship and mentoring programs in the UK via the Professor Christopher R Lowe Carpe Diem Enterprise Fund and has backed over 30 start-up life science, technology and social enterprises. This led to him recently being conferred with a lifetime-held Queens Award for Enterprise Promotion in the 2016 Birthday Honours List. He is an Honorary Fellow at the Judge Business School and Enterprise Fellow at the Department of Chemical Engineering and Institute of Biotechnology both at the University of Cambridge and an advisor on science and industry to the University of Salford. His is currently Director and co-founder of Avvinity Therapeutics Ltd and GeoSpock Ltd, Chairman of Desktop Genetics Ltd, Director of Celixir Ltd and HealX Ltd, Board Member of the UK BioIndustry Association, Chairman of Trustees at Footprint Cafés CIO and serves on the advisory boards of Axol Bioscience Ltd, Biotech and Money, the Cambridge Science Centre, The Cambridge Phenomenon, GeneAdviser Ltd and Simprints. https://www.linkedin.com/in/darrin-m-disley-7b1b8887

For further information, please contact: Zoë Buckingham, Public Relations to PiR Tel: +44 (0)7714 837426 Email: zoe@zoebuckingham.com PiR has a limited number of places remaining for senior members of life science organisations. To register, please contact jfergusson@pir-resourcing.com